

# Cover Sheet

**Study Title: MUCINEX for Treatment of Filamentary Keratitis**

**NCT No: NCT02859246**

**Date: 7/21/2019**

## Statistical Analysis Performed

G. Coco, et al.

The Ocular Surface 17 (2019) 565–570




Fig. 2. Graph showing the number of filaments at baseline and 4 weeks after the addition of oral guaifenesin. (A) Cumulative filament number in all patients who received oral guaifenesin. (B) Separate analysis for patients who only added oral guaifenesin as a new treatment at baseline and patients who received oral guaifenesin and an increase in topical corticosteroids simultaneously.




Fig. 3. Graph showing symptoms score (OSDI) at baseline and 4 weeks after the addition of oral guaifenesin. (A) Cumulative OSDI score in all patients who received oral guaifenesin. (B) Separate analysis for patients who only added oral guaifenesin as a new treatment at baseline and patients who received oral guaifenesin and an increase in topical corticosteroids simultaneously.

## Statistical Test of Hypothesis

We calculated the difference in the mean number of filaments and OSDI score between baseline and follow-up visits and evaluated their change over time. We used the paired-sample Wilcoxon signed-rank test if data did not follow a normal distribution and the paired Student t-test in the case of normally distributed data. For all the analyses we considered the average value of both eyes for all variables with the exception of symptom scores (OSDI), which were considered per patient. Data are presented as the mean  $\pm$  standard deviation (SD), a range for continuous variables, and percentages for categorical variables. A twotail P value of less than 0.05 was considered statistically significant in all statistical tests. The statistical analysis was performed using STATA 13.0 (StataCorp, College Station, TX).